398 related articles for article (PubMed ID: 33301706)
1. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
3. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
[TBL] [Abstract][Full Text] [Related]
4. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms.
Pritchard JE; Pearce JE; Snoeren IAM; Fuchs SNR; Götz K; Peisker F; Wagner S; Benabid A; Lutterbach N; Klöker V; Nagai JS; Hannani MT; Galyga AK; Sistemich E; Banjanin B; Flosdorf N; Bindels E; Olschok K; Biaesch K; Chatain N; Bhagwat N; Dunbar A; Sarkis R; Naveiras O; Berres ML; Koschmieder S; Levine RL; Costa IG; Gleitz HFE; Kramann R; Schneider RK
Cell Rep; 2024 Jan; 43(1):113608. PubMed ID: 38117649
[TBL] [Abstract][Full Text] [Related]
6. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
8. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Dunbar AJ; Kim D; Lu M; Farina M; Bowman RL; Yang JL; Park Y; Karzai A; Xiao W; Zaroogian Z; O'Connor K; Mowla S; Gobbo F; Verachi P; Martelli F; Sarli G; Xia L; Elmansy N; Kleppe M; Chen Z; Xiao Y; McGovern E; Snyder J; Krishnan A; Hill C; Cordner K; Zouak A; Salama ME; Yohai J; Tucker E; Chen J; Zhou J; McConnell T; Migliaccio AR; Koche R; Rampal R; Fan R; Levine RL; Hoffman R
Blood; 2023 May; 141(20):2508-2519. PubMed ID: 36800567
[TBL] [Abstract][Full Text] [Related]
9. Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.
Gleitz HF; Kramann R; Schneider RK
J Pathol; 2018 Jun; 245(2):138-146. PubMed ID: 29570794
[TBL] [Abstract][Full Text] [Related]
10. [The role of fibrocytes in myelofibrosis and fibrocyte regulation as a novel treatment approach].
Maekawa T; Kato S; Kimura F
Rinsho Ketsueki; 2020; 61(1):3-10. PubMed ID: 32023599
[TBL] [Abstract][Full Text] [Related]
11. Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.
Schneider RK; Ziegler S; Leisten I; Ferreira MS; Schumacher A; Rath B; Fahrenkamp D; Müller-Newen G; Crysandt M; Wilop S; Jost E; Koschmieder S; Knüchel R; Brümmendorf TH; Ziegler P
J Hematol Oncol; 2014 Dec; 7():92. PubMed ID: 25498831
[TBL] [Abstract][Full Text] [Related]
12. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis.
Vincelette ND; Yu X; Kuykendall AT; Moon J; Su S; Cheng CH; Sammut R; Razabdouski TN; Nguyen HV; Eksioglu EA; Chan O; Al Ali N; Patel PC; Lee DH; Nakanishi S; Ferreira RB; Hyjek E; Mo Q; Cory S; Lawrence HR; Zhang L; Murphy DJ; Komrokji RS; Lee D; Kaufmann SH; Cleveland JL; Yun S
Blood Cancer Discov; 2024 May; ():. PubMed ID: 38713018
[TBL] [Abstract][Full Text] [Related]
13. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.
Longhitano L; Tibullo D; Vicario N; Giallongo C; La Spina E; Romano A; Lombardo S; Moretti M; Masia F; Coda ARD; Venuto S; Fontana P; Parenti R; Li Volti G; Di Rosa M; Palumbo GA; Liso A
Aging (Albany NY); 2021 Dec; 13(23):25055-25071. PubMed ID: 34905501
[TBL] [Abstract][Full Text] [Related]
14. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms.
Gleitz HFE; Benabid A; Schneider RK
Curr Opin Hematol; 2021 Sep; 28(5):364-371. PubMed ID: 34232140
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Varricchio L; Hoffman R
Front Oncol; 2022; 12():906698. PubMed ID: 35646681
[TBL] [Abstract][Full Text] [Related]
16. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
17. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.
Han Y; Yue L; Wei M; Ren X; Shao Z; Zhang L; Levine RL; Epling-Burnette PK
PLoS One; 2017; 12(1):e0166014. PubMed ID: 28135282
[TBL] [Abstract][Full Text] [Related]
19. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Pieri L; Torossian F; Golub R; Schmutz S; Anginot A; Guerton B; Rochet N; Albanese P; Henault E; Pierre-Louis O; Souraud JB; de Revel T; Dupriez B; Ianotto JC; Bourgeade MF; Vannucchi AM; Lataillade JJ; Le Bousse-Kerdilès MC
Cancer Res; 2015 Nov; 75(22):4753-65. PubMed ID: 26404004
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
